<DOC>
	<DOCNO>NCT01114061</DOCNO>
	<brief_summary>The aim study test performance InsuPatch device daily life . The primary target study evaluate safety aspect daily device use . Additional aspect evaluate study : effect device post prandial glucose level .</brief_summary>
	<brief_title>Evaluation Effects Heating Vicinity Insulin Delivery Site InsuPatch Device During Daily Life</brief_title>
	<detailed_description>Despite recent year advance rapid act insulin analogue early postprandial hyperglycemia late post prandial hypoglycemia still common insulin treat diabetic patient . It appear even rapid act insulin still significant delay time variability delay time change blood glucose level follow meal absorption kinetics insulin inject subcutaneously . Past study use regular human insulin demonstrate use local stimulation injection site dramatically improve regular insulin kinetics . The assumption local stimulation induces local increase blood perfusion improve insulin absorption injection site . Following Insulin develop InsuPatch device . The intend use InsuPatch device improve insulin delivery blood insulin infuse use insulin-infusion pump control heating area surround point infusion . The InsuPatch device consist two component : I ) InsuPatch single-use , flat , heat pad electrical wire attach adhesive bottom Medtronic MiniMed Quick-set® infusion set . The user attach device infusion set prior insertion infusion set catheter . II ) The InsuPatch case use case Medtronic MiniMed Paradigm insulin infusion pump . The InsuPatch case contain electronic unit battery . The effect device pharmacokinetics ( PK ) pharmacodynamics ( PD ) inject insulin test Euglycemic clamp meal tolerance test ( MTT ) study . The effect device insulin PK evaluate compare insulin concentration meal MTT study without operation device . The effect device insulin PD evaluate use Euglycemic clamp protocol without operation device . The effect device postprandial glucose excursion test compare post meal glucose level without operation device . The main result study : 1 . An increase 49 % available insulin blood first 30 minute post injection 37 % first hour post injection ( PK ) . 2 . A reduction 25 % average glucose level post-meal first two hour ( PD ) . 3 . A reduction 43 % time peak action insulin ( PD ) . The aim study test performance InsuPatch device daily life . The primary target study evaluate safety aspect daily device use . Additional aspect evaluate study : effect device post prandial glucose level .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Participant age 18 65 year old ( include = 18 year =65 year ) 2 . BMI : 1835 kg/m2 3 . Insulin dependent diabetes insulin pump . 4 . Use shortacting insulin analogue 5 . Subjects agree use InsuPatch device . 6 . 6 % ≤ HbA1c ≤ 9.5 % 7 . Agree sign consent form . 8 . Subject willing least 4 blood glucose recording per day 9 . Subject understands study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform 10 . Willing comply specify followup evaluation 1 . Pregnancy 2 . Breast feeding woman . 3 . Alcohol addiction 4 . Had CABG ( Coronary Artery Bypass Graft ) , Post MI ( Myocardial Infarction ) active Ischemic heart disease last 3 month prior study date 5 . Had CVA ( cardiovascular accident ) TIA ( transient ischemic accident ) last 12 month prior study 6 . Suffer Hypertension ( blood pressure &gt; 140/90 ) . 7 . Low blood hemoglobin concentration &lt; 9 g/dL female &lt; 11g/dL male . 8 . Known gastro enteroparesis 9 . Abnormal kidney and/ liver function test . ( Creatinine &gt; 1.5 mg/dL , liver test &gt; 2 time upper limit normal range ) . 10 . Severe hypoglycemic event require glucagon injection glucose infusion within last six month prior study inclusion 11 . Hypoglycaemia unawareness 12 . Diabetic ketoacidosis ( severe , hospitalization ) within last six month prior study inclusion 13 . Psychological incompetence 14 . Signs drug abuse 15 . Any clinical condition history , seem relevant principle investigator disqualify participant . 16 . Not willing sign inform consent form . 17 . Subjects diminish skin integrity , Excessive fibrosis , lipohypertrophy eczema infusion sit 18 . Subjects heat sensitivity 19 . Subjects involve planed participate study . 20 . Any subject primary researcher consider suit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>diabetes</keyword>
	<keyword>postprandial glucose level</keyword>
	<keyword>insulin pharmacodynamics</keyword>
	<keyword>Insulin Pharmacokinetics</keyword>
</DOC>